Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
D000483:Alleles; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D019556:COS Cells; D019496:Cancer Vaccines; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry; D015234:HLA-A Antigens / Q000096:biosynthesis*; D059870:HLA-A11 Antigen; D015791:HLA-A3 Antigen / Q000096:biosynthesis*; D006801:Humans; D007167:Immunotherapy; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism*; D010455:Peptides / Q000737:chemistry*; D011485:Protein Binding; D012878:Skin Neoplasms / Q000276:immunology / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism; D022223:Vaccines, Subunit / Q000737:chemistry
D019496:Cancer Vaccines; D018076:DNA, Complementary; D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; C082945:HLA-A*33 antigen; D059870:HLA-A11 Antigen; D015791:HLA-A3 Antigen; C069527:HLA-A31 antigen; D010455:Peptides; D022223:Vaccines, Subunit